These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 16780807

  • 1. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
    Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y, Pinkas-Kramarski R.
    Biochem Pharmacol; 2006 Aug 14; 72(4):427-36. PubMed ID: 16780807
    [Abstract] [Full Text] [Related]

  • 2. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
    Khwaja A, Sharpe CC, Noor M, Kloog Y, Hendry BM.
    Kidney Int; 2005 Aug 14; 68(2):474-86. PubMed ID: 16014024
    [Abstract] [Full Text] [Related]

  • 3. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition.
    Blum R, Nakdimon I, Goldberg L, Elkon R, Shamir R, Rechavi G, Kloog Y.
    Int J Cancer; 2006 Aug 01; 119(3):527-38. PubMed ID: 16496386
    [Abstract] [Full Text] [Related]

  • 4. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
    Stärkel P, Charette N, Borbath I, Schneider-Merck T, De Saeger C, Abarca J, Leclercq I, Horsmans Y.
    Mol Carcinog; 2012 Oct 01; 51(10):816-25. PubMed ID: 21882255
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
    Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y.
    Clin Cancer Res; 2002 Feb 01; 8(2):555-65. PubMed ID: 11839677
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
    Yaari-Stark S, Shaked M, Nevo-Caspi Y, Jacob-Hircsh J, Shamir R, Rechavi G, Kloog Y.
    Int J Cancer; 2010 May 15; 126(10):2268-81. PubMed ID: 19998334
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
    Zhao Y, Fan D, Ru B, Cheng KW, Hu S, Zhang J, Li ET, Wang M.
    Eur J Cancer; 2016 Nov 15; 68():38-50. PubMed ID: 27710830
    [Abstract] [Full Text] [Related]

  • 11. Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells.
    Santen RJ, Lynch AR, Neal LR, McPherson RA, Yue W.
    Anticancer Drugs; 2006 Jan 15; 17(1):33-40. PubMed ID: 16317288
    [Abstract] [Full Text] [Related]

  • 12. Ras inhibition enhances autophagy, which partially protects cells from death.
    Schmukler E, Grinboim E, Schokoroy S, Amir A, Wolfson E, Kloog Y, Pinkas-Kramarski R.
    Oncotarget; 2013 Jan 15; 4(1):145-55. PubMed ID: 23370967
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A.
    J Cell Physiol; 2007 May 15; 211(2):533-43. PubMed ID: 17192846
    [Abstract] [Full Text] [Related]

  • 16. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
    Jiang C, Song T, Li J, Ao F, Gong X, Lu Y, Zhang C, Chen L, Liu Y, He H, Huang O.
    Mol Neurobiol; 2017 Jan 15; 54(1):779-787. PubMed ID: 27021020
    [Abstract] [Full Text] [Related]

  • 17. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y.
    Clin Cancer Res; 2006 Sep 15; 12(18):5533-42. PubMed ID: 17000690
    [Abstract] [Full Text] [Related]

  • 18. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells.
    Fribourg AF, Knudsen KE, Strobeck MW, Lindhorst CM, Knudsen ES.
    Cell Growth Differ; 2000 Jul 15; 11(7):361-72. PubMed ID: 10939590
    [Abstract] [Full Text] [Related]

  • 19. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
    Barkan B, Kloog Y, Ehrlich M.
    Mol Cancer Ther; 2011 Aug 15; 10(8):1317-26. PubMed ID: 21632464
    [Abstract] [Full Text] [Related]

  • 20. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
    Choi HE, Shin JS, Leem DG, Kim SD, Cho WJ, Lee KT.
    Chem Biol Interact; 2016 Dec 25; 260():196-207. PubMed ID: 27720946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.